GLP-1s, Weight Loss, and the Stigma We Don’t Talk About
A recent report highlighted a surprising trend: individuals using GLP-1 medications such as Ozempic and Wegovy may be facing even more social stigma than those who remain overweight. And while neither deserves any stigma at all, it raises an important question about how we judge health choices in modern medicine.
In this conversation, Dr. Bret Scher reflects on whether his own critiques of GLP-1 medications stem from bias against the individuals using them. His conclusion is clear: the issue is not the patient, but the system surrounding care.
While GLP-1 receptor agonists can be powerful…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.